GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MYND Life Sciences Inc (XCNQ:MYND) » Definitions » Inventories, Inventories Adjustments

MYND Life Sciences (XCNQ:MYND) Inventories, Inventories Adjustments : C$0.00 Mil (As of Jul. 2024)


View and export this data going back to 2021. Start your Free Trial

What is MYND Life Sciences Inventories, Inventories Adjustments?

MYND Life Sciences's Inventories, Inventories Adjustments for the quarter that ended in Jul. 2024 was C$0.00 Mil.


MYND Life Sciences Inventories, Inventories Adjustments Historical Data

The historical data trend for MYND Life Sciences's Inventories, Inventories Adjustments can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MYND Life Sciences Inventories, Inventories Adjustments Chart

MYND Life Sciences Annual Data
Trend Oct21 Oct22 Oct23
Inventories, Inventories Adjustments
- - -

MYND Life Sciences Quarterly Data
Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
Inventories, Inventories Adjustments Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

MYND Life Sciences Inventories, Inventories Adjustments Calculation

Inventories, Inventories Adjustments represents certain charges made in the current period in inventory resulting from breakage, spoilage, employee theft and shoplifting, etc.


MYND Life Sciences Business Description

Industry
Traded in Other Exchanges
Address
105-2248 Elgin Avenue, Port Coquitlam, BC, CAN, V3C 2B2
MYND Life Sciences Inc is a medical biotech drug research and development company. The company is focused on neuro pharmaceutical and novel drug development, diagnostics, and vaccines and is developing new biological entities (NBEs) and new chemical entities (NCEs) and differentiates itself from other (bio)pharmaceutical companies by different molecular concepts for the applications of psilocybin analogs for overcoming diseases.